Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases | Hematology
Clinical Trials: Venous Thrombosis
A listing of clinical trials currently looking for volunteers to enroll in Venous Thrombosis studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
Clarification of Optimal Anticoagulation Through Genetics
Dothan :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Arizona
Glendale : Arrowhead Hospital/Phoenix Heart, PLLC
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Arkansas
California
Los Angeles :
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Orange : St. Joseph Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Palo Alto : Stanford University Medical Center
Treatment of Blood Clots in Children With Cancer
San Francisco : University of California San Francisco
Clarification of Optimal Anticoagulation Through Genetics
Stanford : Stanford University Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Connecticut
Danbury : Danbury Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Norwich : Eastern Connecticut Hematology and Oncology Associates
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Delaware
Newark : Christiana Care Health Systems
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
District of Columbia
Florida
Clearwater :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Ft. Myers :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Gainesville : University of Florida
Clarification of Optimal Anticoagulation Through Genetics
Jacksonville : Nemours Children's Clinic/Jacksonville
Treatment of Blood Clots in Children With Cancer
Orlando : Florida Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
View More »
Tampa : Pepin Heart Hospital / University Community Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Tampa : St. Joseph's Children's Hospital of TampaPediatric Hematology/Oncology Research Department
Treatment of Blood Clots in Children With Cancer
Georgia
Atlanta : Emory University
Treatment of Blood Clots in Children With Cancer
Augusta : Georgia Health Sciences University
Clarification of Optimal Anticoagulation Through Genetics
Jonesboro :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Illinois
Chicago : University of Illinois at Chicago
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Chicago : Rush University Medical Center
Treatment of Blood Clots in Children With Cancer
Hinsdale : Adventist Midwest Health
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Springfield : Prairie Education and Research Cooperative
A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
Springfield : Southern Illinois University
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
View More »
Winfield : Central DuPage Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Indiana
Indianapolis : CorVasc
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Lafayette :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Iowa
Iowa City : University of Iowa Carver's College of Medicine
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Kentucky
Louisiana
Covington :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
New Orleans : Tulane University Health Science Center
Clarification of Optimal Anticoagulation Through Genetics
Maine
Portland : Maine Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Maryland
Baltimore : Johns Hopkins Bayview Medical Center
A Pilot Study Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients
Baltimore : University of Maryland School of Medicine
Clarification of Optimal Anticoagulation Through Genetics
Massachusetts
Boston : Massachusetts General Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Michigan
Ann Arbor : Ann Arbor Veteran's Administration Health System
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Ann Arbor : University of Michigan Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Detroit : Henry Ford Health System
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Detroit : Henry Ford Hospital
Clarification of Optimal Anticoagulation Through Genetics
Minnesota
Rochester : Mayo Clinic
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Rochester : Mayo Clinic College of Medicine
Clarification of Optimal Anticoagulation Through Genetics
Missouri
St. Louis : Washington University School of Medicine
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
St. Louis : Washington University School of Medicine
Clarification of Optimal Anticoagulation Through Genetics
Montana
Butte :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Nebraska
Lincoln : Saint Elizabeth Regional Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
New Jersey
Teaneck : Holy Name Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
New Mexico
Albuquerque : University of New Mexico
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Albuquerque : University of New Mexico
Treatment of Blood Clots in Children With Cancer
New York
Bronx : Montefiore Medical Center
Clarification of Optimal Anticoagulation Through Genetics
New York : Cornell Weill Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
New York : Mount Sinai School of Medicine
Clarification of Optimal Anticoagulation Through Genetics
Staten Island : Staten Island University Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
North Carolina
Chapel Hill : University of North Carolina at Chapel Hill
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Durham : Duke University
Clarification of Optimal Anticoagulation Through Genetics
Durham : Duke Children's Hospital
Treatment of Blood Clots in Children With Cancer
Winston Salem : Wake Forest University Baptist Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Winston-Salem : Forsyth Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Ohio
Cincinatti : Good Samaritan Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Cleveland : Cleveland Clinic
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Colombus : Univeristy Medical Center
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Columbus : Riverside Methodist Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Toledo : Jobst Vascular Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Oregon
Portland : Oregon Health & Science University
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Portland : Oregon Health and Science University
Treatment of Blood Clots in Children With Cancer
Pennsylvania
West Reading : The Reading Hospital and Medical Center Clinical Trials Office
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
View More »
Bethlehem : St. Luke's Hospital and Health Network
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Camp Hill :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Ephrata :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Philadelphia : Albert Einstein Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Philadelphia : Temple University Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Philadelphia : Hospital of the University of Pennsylvania
Clarification of Optimal Anticoagulation Through Genetics
Pittsburgh : Allegheny General Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Pittsburgh : University of Pittsburgh Medical Center Presbyterian Shadyside
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Pittsburgh : The Western Pennsylvania Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Sellersville :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
West Reading : The Reading Hospital and Medical Center
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Rhode Island
Providence : Rhode Island Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
South Carolina
Charleston : Medical University of South Carolina
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Charleston : Medical Center of South Carolina
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Tennessee
Memphis : St. Jude Children's Research Hospital
Treatment of Blood Clots in Children With Cancer
Nashville : Vanderbilt University
Clarification of Optimal Anticoagulation Through Genetics
Texas
Forth Worth : Cook Children's Medical Center
Treatment of Blood Clots in Children With Cancer
Galveston : University of Texas Medical Branch
Clarification of Optimal Anticoagulation Through Genetics
Utah
Murray : Intermountain Medical Center
Clarification of Optimal Anticoagulation Through Genetics
Salt Lake City : University of Utah
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Salt Lake City : University of Utah Health Care
Clarification of Optimal Anticoagulation Through Genetics
Virginia
Charlottesville : University of Virginia Health System
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Fredericksburg :
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Washington
Tacoma : MultiCare Health System
A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Wisconsin
Marshfield : Marshfield Clinical Research Foundation
Clarification of Optimal Anticoagulation Through Genetics
Milwaukee : Medical College of Wisconsin/Froedtert Hospital
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Australia
Melbourne : Royal Melbourne hospital
The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.
Parkville :
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Austria
Graz : 1160.86.43001 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Many Locations :
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Wien :
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Wien : 1160.89.43001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Wien : 1160.86.43003 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Belgium
Brussel : 1160.89.32003 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Ghent : Drug Research Unit Ghent
A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.
Canada
Charlottetown : 1160.86.01003 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Edmonton :
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Edmonton : 1160.89.00002 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Hamilton :
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Hamilton : St. Joseph's Healthcare Hamilton
The Risk of Venous Clotting in Patients After Renal Transplant
View More »
Hamilton : St Joseph's Healthcare Hamilton
Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
Montréal : Maisonneuve Rosemont Hospital
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Ottawa : 1160.89.00001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Ottawa : Ottawa Hospital, Parkdale Clinic
Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
Red Deer : 1160.86.01001 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Toronto : St. Michael's Hospital
Atorvastatin for the Treatment of Retinal Vein Occlusion
Toronto : 1160.89.00005 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Vancouver : Diamond Health Care Centre
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
Czech Republic
Brno : 1160.86.42001 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Olomouc : 1160.86.42003 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Prague : 1160.86.42004 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Prague 5 : 1160.86.42002 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Denmark
Many Locations :
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Finland
Jyväskylä : 1160.86.35801 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
France
Dijon : University Hospital
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Grenoble : University Hospital
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Many Locations :
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Marseille : 1160.89.33002 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Montelimar : Cabinet
Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome
View More »
Paris : 1160.89.33001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Germany
Baesweiler : Chriurgische Praxisklinik
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Berlin : DEutsches Rotes Kreuz Schwesternschaft Berlin Gemeinnütziges Krankenhaus GmbH
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Bonn : Universitäts-Hautklinik Bonn
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Dresden : Universitätsklinikum Dresden
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Freiburg : Hautarztpraxis
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
View More »
Karlsbach : Akademie für Gefäßkrankheiten e.V.
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Many Locations :
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Mühldorf am Inn : Kardiologie Mühldorf am Inn
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
München : Gemeinschaftspraxis Mietaschk, Bilderling, Kaiser, Tato
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Israel
Tel Hashomer :
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Italy
Bologna : University Hospital
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Genova :
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Milan : IRCCS H San Raffaele
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Roma : 1160.89.39001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Japan
Aomori :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Bunkyo-ku :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Chuoku :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Fukuoka :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Itabashi-ku :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
View More »
Kahoku-gun :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Kanazawa :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Kumamoto :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Maebashi :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Niigata :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Osaka :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Osakasayama :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Sakura :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Sapporo :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Sasebo :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Shinjuku-ku :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Shizuoka :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Tokushima :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Toyoake :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Tsu :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Wakayama :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Yokohama :
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Latvia
Riga : 1160.89.37101 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Lithuania
Vilnius : 1160.89.37001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Netherlands
Nijmegen : 1160.89.31003 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Utrecht : 1160.89.31004 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Norway
Bergen : 1160.89.47001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Spain
Alicante : University Hospital
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Madrid : 1160.89.34002 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Madrid : 1160.89.34001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Many Locations :
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Soria : General Hospital
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Sweden
Hässleholm : 1160.86.46002 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Many Locations :
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Mölndal : 1160.86.46001 Boehringer Ingelheim Investigational Site
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Stockholm : Karolinska University Hospital
Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture
Switzerland
Many Locations :
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Zürich : 1160.89.41001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Thailand
Bangkok : 1160.89.66001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Tunisia
Tunis : Hospital Charle Nicolle
Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin
Ukraine
Dnipropetrovsk : 1160.89.38001 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Lugansk : 1160.89.38002 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Vinnytsya : 1160.89.38003 Boehringer Ingelheim Investigational Site
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
